LOGIN  |  REGISTER
Amneal Pharmaceuticals
Cue Biopharma

Warby Parker to Announce Fourth Quarter and Full Year 2022 Financial Results on February 28, 2023

February 07, 2023 | Last Trade: US$23.27 0.21 0.91

NEW YORK / Feb 07, 2023 / Business Wire / Warby Parker Inc. (NYSE: WRBY) (the “Company”), a direct-to-consumer lifestyle brand focused on vision for all, today announced that its financial results for the fourth quarter and full year ended December 31, 2022, will be released before market open on February 28, 2023.

In addition, the Company will discuss its results and business outlook during a live conference call and webcast at 8:00 a.m. Eastern Time. The conference call can be accessed by dialing 844-200-6205 from the U.S. or 929-526-1599 from international locations. The conference passcode is 045225.

A live webcast of the conference call will be available on the investors section of the Company’s website at https:investors.warbyparker.com where presentation materials will also be posted prior to the conference call. A replay will be made available online approximately 2 hours following the live call for a period of 90 days.

About Warby Parker

Warby Parker (NYSE: WRBY) was founded in 2010 with a mission to inspire and impact the world with vision, purpose, and style–without charging a premium for it. Headquartered in New York City, the co-founder-led lifestyle brand pioneers ideas, designs products, and develops technologies that help people see, from designer-quality prescription glasses (starting at $95) and contacts, to eye exams and vision tests available online and in more than 190 retail stores across the U.S. and Canada.

Warby Parker aims to demonstrate that businesses can scale while doing good in the world. Ultimately, the brand believes in vision for all, which is why for every pair of glasses or sunglasses sold, they distribute a pair to someone in need through their Buy a Pair, Give a Pair program. To date, Warby Parker has worked alongside its nonprofit partners to distribute more than ten million glasses to people in need.

Viking Therapeutics

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB